DDInter1346 DDInter927
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Orciprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Orciprenaline {u} (Compound) resembles {v} (Compound) Fenoterol
Orciprenaline {u} (Compound) resembles {v} (Compound) Terbutaline
Orciprenaline {u} (Compound) treats {v} (Disease) asthma
Orciprenaline {u} (Compound) binds {v} (Gene) ADRB2
Orciprenaline {u} (Compound) upregulates {v} (Gene) DDX10
Orciprenaline {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Orciprenaline {u} (Compound) downregulates {v} (Gene) SLC2A6
Orciprenaline {u} (Compound) causes {v} (Side Effect) Dizziness
Orciprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Betamethasone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Orciprenaline (Compound) resembles Fenoterol (Compound)
Orciprenaline (Compound) resembles Terbutaline (Compound)
Orciprenaline (Compound) treats asthma (Disease)
Orciprenaline (Compound) binds ADRB2 (Gene)
Orciprenaline (Compound) upregulates DDX10 (Gene)
Orciprenaline (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Orciprenaline (Compound) downregulates SLC2A6 (Gene)
Orciprenaline (Compound) causes Dizziness (Side Effect)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Betamethasone